Repare Therapeutics/$RPTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Repare Therapeutics
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Ticker
$RPTX
Sector
Primary listing
Employees
129
Headquarters
Montreal, Canada
Website
RPTX Metrics
BasicAdvanced
$111M
-
-$1.69
1.04
-
Price and volume
Market cap
$111M
Beta
1.04
52-week high
$2.66
52-week low
$0.89
Average daily volume
1.2M
Financial strength
Current ratio
10.708
Quick ratio
10.404
Total debt to equity
0.297
Profitability
EBITDA (TTM)
-76.462
Gross margin (TTM)
403.40%
Net profit margin (TTM)
-608.26%
Operating margin (TTM)
-667.31%
Effective tax rate (TTM)
-1.07%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-29.72%
Return on equity (TTM)
-49.78%
Valuation
Price to revenue (TTM)
9.292
Price to book
0.96
Price to tangible book (TTM)
0.96
Price to free cash flow (TTM)
-1.572
Free cash flow yield (TTM)
-63.60%
Free cash flow per share (TTM)
-1.641
Growth
Revenue change (TTM)
-82.16%
Earnings per share change (TTM)
-14.69%
3-year revenue growth (CAGR)
-53.82%
3-year earnings per share growth (CAGR)
39.72%
What the Analysts think about RPTX
Analyst ratings (Buy, Hold, Sell) for Repare Therapeutics stock.
RPTX Financial Performance
Revenues and expenses
RPTX Earnings Performance
Company profitability
RPTX News
AllArticlesVideos
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Business Wire·4 days ago
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Business Wire·4 weeks ago
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repare Therapeutics stock?
Repare Therapeutics (RPTX) has a market cap of $111M as of January 20, 2026.
What is the P/E ratio for Repare Therapeutics stock?
The price to earnings (P/E) ratio for Repare Therapeutics (RPTX) stock is 0 as of January 20, 2026.
Does Repare Therapeutics stock pay dividends?
No, Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders as of January 20, 2026.
When is the next Repare Therapeutics dividend payment date?
Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Repare Therapeutics?
Repare Therapeutics (RPTX) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.